ANVS - Annovis Bio Inc

2.5
-0.080   -3.200%

Share volume: 435,024
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$2.58
-0.08
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.72%
1 Month
2.88%
3 Months
-39.47%
6 Months
0.81%
1 Year
47.06%
2 Year
-73.23%
Key data
Stock price
$2.50
P/E Ratio 
0.00
DAY RANGE
$2.44 - $2.68
EPS 
-$1.52
52 WEEK RANGE
$1.11 - $5.50
52 WEEK CHANGE
$51.52
MARKET CAP 
40.336 M
YIELD 
N/A
SHARES OUTSTANDING 
26.503 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
4.62
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$303,567
AVERAGE 30 VOLUME 
$336,034
Company detail
CEO: Maria-Luisa Maccecchini
Region: US
Website: annovisbio.com
Employees: 3
IPO year: 2020
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for Alzheimer's disease.

Recent news